Malignancy Rate of Indeterminate Findings on FDG-PET/CT in Cutaneous Melanoma Patients.
BACKGROUND
The use of 18F-2-Fluor-2-desoxy-D-glucose Positron Emission Tomography/Computed Tomography FDG-PET/CT in clinical routine for staging, treatment response monitoring and post treatment surveillance in metastatic melanoma patients has noticeably increased due to significant improvement of the overall survival rate in melanoma patients. However, determining the dignity of the findings with increased metabolic activity on FDG-PET/CT can be sometimes challenging and may need further investigation.


PURPOSE
We aimed to investigate the malignancy rate of indeterminate findings on FDG-PET/CT in metastatic cutaneous melanoma patients.


METHODS
This single-center retrospective study included cutaneous melanoma patients who underwent FDG-PET/CT in clinical routine between 2015 and 2017 with findings reported as indeterminate and therefore requiring further evaluation. The dignity of the included findings was determined by subsequent imaging and, if required, additional histopathology. The impact of the outcome on the clinical management was also reported.


RESULTS
A total of 842 FDG-PET/CT reports of 244 metastatic cutaneous melanoma patients were reviewed. Sixty indeterminate findings were included. Almost half of all indeterminate findings were lymph nodes, lung nodules and cerebral lesions. In total, 43.3% of all included findings proved to be malignant. 81% of all malignant lesions were metastases of cutaneous melanoma, while 19% of all malignant lesions could be attributed to other primary malignancies, such as lung, breast, thyroid and colorectal cancers. Malignant findings influenced clinical management in 60% of the cases.


CONCLUSION
Indeterminate findings on FDG-PET/CT in metastatic cutaneous melanoma patients should be further investigated. Almost one out of every two indeterminate findings on FDG-PET/CT is malignant. The majority of the findings are melanoma manifestations, however, in a significant percentage, other primary tumors are found. Upon verification, patient management is changed in most cases.
['Kudura|Ken|K|', 'Dimitriou|Florentia|F|', 'Mihic-Probst|Daniela|D|', 'Muehlematter|Urs J|UJ|', 'Kutzker|Tim|T|', 'Basler|Lucas|L|', 'Förster|Robert|R|0000-0002-7664-9207', 'Dummer|Reinhard|R|', 'Mangana|Joanna|J|', 'Husmann|Lars|L|', 'Burger|Irene A|IA|', 'Kreissl|Michael Christoph|MC|0000-0001-5905-6015']
melanoma positron emission tomography computed tomography immunotherapy